Checkmate Pharmaceuticals, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Checkmate Pharmaceuticals, Inc.
Equities
CMPI
US1628181083
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |